MCID: TRY001
MIFTS: 50

Trypanosomiasis

Categories: Infectious diseases

Aliases & Classifications for Trypanosomiasis

MalaCards integrated aliases for Trypanosomiasis:

Name: Trypanosomiasis 12 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10113
ICD9CM 34 086 086.9
MeSH 43 D014352
SNOMED-CT 67 78940002
ICD10 32 B57.2
UMLS 71 C0041227

Summaries for Trypanosomiasis

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans.

MalaCards based summary : Trypanosomiasis is related to sleeping sickness and chagas disease. An important gene associated with Trypanosomiasis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Anti-Infective Agents and Antiparasitic Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are cellular and cardiovascular system

Wikipedia : 74 Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic... more...

Related Diseases for Trypanosomiasis

Diseases related to Trypanosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 sleeping sickness 34.4 ODC1 IL6 IL10 HPR HP APOL1
2 chagas disease 33.4 TNF TLR9 TLR2 ODC1 MYD88 IL6
3 meningoencephalitis 31.8 TNF IL6 IL10 ALB
4 encephalitis 31.6 TNF IL6 IL1B IL10 IDO1 CCL2
5 myocarditis 31.2 TNF IL6 IL4 IL1B IL10 IFNG
6 schistosomiasis 31.1 TNF IL4 IL10 IFNG CCL2 ALB
7 congestive heart failure 31.1 TNF KNG1 IL6 ALB
8 disseminated intravascular coagulation 31.0 TNF IL6 IL10
9 mouth disease 31.0 IL6 IL1B IL10 IFNG
10 acquired immunodeficiency syndrome 31.0 TNF IL6 IL1B IL10 IFNG APOA1
11 glomerulonephritis 31.0 TLR9 IL1B CCL2 ALB
12 myositis 31.0 TNF IL6 IL1B IFNG CXCL8
13 filariasis 30.9 TNF TLR9 TLR2 IL6 IL10 IFNG
14 intracranial hypertension 30.9 TNF IL1B ALB
15 echinococcosis 30.9 TNF TLR2 IL6 IL10 IFNG
16 nervous system disease 30.9 TNF IL6 IL1B IFNG ALB
17 diarrhea 30.8 TNF IL6 IL1B IL10 IFNG CXCL8
18 human immunodeficiency virus infectious disease 30.8 TNF TLR9 IL4 IL10 IFNG IDO1
19 choroiditis 30.8 TNF IL10 IFNG
20 mucocutaneous leishmaniasis 30.8 TNF TLR9 IL4 IL10 IFNG
21 immune deficiency disease 30.8 TNF IL6 IL4 IL10 IFNG IDO1
22 orchitis 30.8 TNF IL6 IL10
23 spotted fever 30.8 TNF IL10 IFNG IDO1
24 exanthem 30.8 TNF IL6 IL10 CXCL8 ALB
25 myelitis 30.8 TNF IL6 IL10 CXCL8
26 chorioretinitis 30.8 TNF IL6 IL10 IFNG
27 lymphopenia 30.8 IL6 IL4 IL10 IFNG
28 cysticercosis 30.8 IL6 IL1B IL10
29 trichomoniasis 30.8 TNF IL6 CXCL8
30 endomyocardial fibrosis 30.8 TNF IL4 IL10
31 cryoglobulinemia 30.8 TNF IL6 IL10 IFNG
32 human immunodeficiency virus type 1 30.8 TNF IL6 IL10 IFNG IDO1 CCL2
33 cerebrovascular disease 30.7 TNF IL6 HP APOA1
34 amebiasis 30.7 TNF TLR2 IL4 CXCL8 ALB
35 filarial elephantiasis 30.7 TLR2 IL4 IL10
36 leishmaniasis 30.7 TNF TLR9 TLR2 ODC1 MYD88 IL6
37 brucellosis 30.7 TNF IL6 IL4 IL10 IFNG CXCL8
38 toxoplasmosis 30.7 TNF TLR9 TLR2 MYD88 IL6 IL4
39 tetanus 30.7 TNF IL6 IL4 IL1B IL10 IFNG
40 thyroiditis 30.7 TNF IL6 IL4 IL10
41 central nervous system disease 30.7 TNF IL6 IL1B IFNG CCL2 ALB
42 respiratory failure 30.7 TNF IL6 IL1B IL10 CXCL8 ALB
43 lymphadenitis 30.6 TNF IL1B IL10 IFNG CXCL8
44 transverse myelitis 30.6 TNF IL6 IL10 CXCL8 APOA1
45 purpura 30.6 TNF IL6 IL4 IL10
46 carpal tunnel syndrome 30.6 IL6 IL1B CCL2
47 rubella 30.6 TNF IL6 IL4 IL10 IFNG
48 brain edema 30.6 KNG1 IL6 IL1B IFNG ALB
49 hypereosinophilic syndrome 30.5 IL4 IL10 IFNG CXCL8
50 lymphocytic choriomeningitis 30.5 TLR2 MYD88 IL6 CXCL8

Graphical network of the top 20 diseases related to Trypanosomiasis:



Diseases related to Trypanosomiasis

Symptoms & Phenotypes for Trypanosomiasis

MGI Mouse Phenotypes related to Trypanosomiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ALB APOA1 HP IDO1 IFNG IL10
2 cardiovascular system MP:0005385 10.2 ALB APOA1 HP IDO1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.13 ALB APOA1 HP IDO1 IFNG IL10
4 hematopoietic system MP:0005397 10.11 HP IDO1 IFNG IL10 IL1B IL4
5 immune system MP:0005387 10.07 ALB CCL2 HP IDO1 IFNG IL10
6 digestive/alimentary MP:0005381 10.06 ALB IFNG IL10 IL4 IL6 MYD88
7 liver/biliary system MP:0005370 9.81 ALB APOA1 HP IFNG IL10 IL4
8 neoplasm MP:0002006 9.61 ALB HP IFNG IL10 IL1B IL6
9 renal/urinary system MP:0005367 9.28 ALB HP IDO1 IFNG IL4 IL6

Drugs & Therapeutics for Trypanosomiasis

Drugs for Trypanosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Infective Agents Phase 4
2 Antiparasitic Agents Phase 4
3 Antiprotozoal Agents Phase 4
4 Immunosuppressive Agents Phase 4
5 Benzonidazole Phase 4
6 Immunologic Factors Phase 4
7
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
8 Nifurtimox Investigational Phase 3 23256-30-6
9 Melarsoprol Investigational Phase 3 494-79-1
10 polysaccharide-K Phase 2, Phase 3
11 Antibodies Phase 2, Phase 3
12 Immunoglobulins Phase 2, Phase 3
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
15
Permethrin Approved, Investigational Phase 2 52645-53-1 40326
16
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
17
Pafuramidine Investigational Phase 2 186953-56-0
18 Antifungal Agents Phase 2
19 Insect Repellents Phase 2
20 Protective Agents Phase 2
21 Immunoglobulin G
22 Immunoglobulin M

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
3 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
4 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
5 Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
6 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
7 Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
8 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
9 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
10 Efficacy and Safety Study of SCYX-7158 in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
11 An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
12 Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial Recruiting NCT03974178 Phase 2, Phase 3 Fexinidazole
13 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Recruiting NCT04099628 Phase 2, Phase 3
14 Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
15 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
16 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
17 Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
18 Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
19 Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
20 A Within-subject Laboratory and Field Trial to Test the Use of Commercially Available Insect Repellents Against Contact From Musca Sorbens, the Putative Vector of Trachoma Suspended NCT03813069 Phase 2
21 Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers Completed NCT01533961 Phase 1 SCYX-7158;Placebo
22 Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers Completed NCT00982904 Phase 1 Fexinidazole/Placebo
23 Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers Completed NCT01340157 Phase 1 Fexinidazole
24 A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition Completed NCT02571062 Phase 1 Fexinidazole
25 Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers. Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
26 Abbott ESA Chagas Assay Post-Market Study Completed NCT01662362
27 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
28 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
29 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Recruiting NCT03356665
30 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure Active, not recruiting NCT03112655
31 Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria Not yet recruiting NCT03394976

Search NIH Clinical Center for Trypanosomiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: trypanosomiasis

Genetic Tests for Trypanosomiasis

Anatomical Context for Trypanosomiasis

MalaCards organs/tissues related to Trypanosomiasis:

40
Testes, Brain, Heart, T Cells, Bone, B Cells, Kidney

Publications for Trypanosomiasis

Articles related to Trypanosomiasis:

(show top 50) (show all 5323)
# Title Authors PMID Year
1
The prolyl oligopeptidase family. 54 61
11915948 2002
2
Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach. 61
32033395 2020
3
Repurposing a polymer precursor: Synthesis and in vitro medicinal potential of ferrocenyl 1,3-benzoxazine derivatives. 61
31855792 2020
4
Trypanosoma cruzi cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity. 61
31593356 2020
5
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. 61
31879061 2020
6
C6-O-alkylated 7-deazainosine nucleoside analogues: Discovery of potent and selective anti-sleeping sickness agents. 61
31931339 2020
7
Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? 61
31952121 2020
8
Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment. 61
31940846 2020
9
Whose Elimination? Frontline Workers' Perspectives on the Elimination of the Human African Trypanosomiasis and Its Anticipated Consequences. 61
31906341 2020
10
Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. 61
31846577 2020
11
Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole. 61
32012658 2020
12
Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). 61
31961872 2020
13
Centering Patient Expectations of a Novel Home-Based Oral Drug Treatment among T. b. rhodesiense Human African Trypanosomiasis Patients in Uganda. 61
31973101 2020
14
mSphere of Influence: Expanding the CRISPR Sphere with Single-Locus Proteomics. 61
31969475 2020
15
Screening for Small Molecule Modulators of Trypanosoma brucei Hsp70 Chaperone Activity Based upon Alcyonarian Coral-Derived Natural Products. 61
32012664 2020
16
Design and synthesis of α-phenoxy-N-sulfonylphenyl acetamides as Trypanosoma brucei Leucyl-tRNA synthetase inhibitors. 61
31732256 2020
17
The use of Sulfonamide Derivatives in the Treatment of Trypanosomatid Parasites including Trypanosoma cruzi, Trypanosoma brucei, and Leishmania ssp. 61
31218962 2020
18
A simple, robust, and affordable bioluminescent assay for drug discovery against infective African trypanosomes. 61
31958156 2020
19
Unusual MRI Findings in African Trypanosoma brucei gambiense Trypanosomiasis: Dentate Nuclei and Hypothalamic Lesions. 61
31971136 2020
20
Establishing Trypanosoma cruzi farnesyl pyrophosphate synthase as a viable target for biosensor driven fragment-based lead discovery. 61
31994261 2020
21
Chagas disease: Historic perspective. 61
32001300 2020
22
Gene expression profiling of Trypanosoma cruzi in the presence of heme points to glycosomal metabolic adaptation of epimastigotes inside the vector. 61
31895927 2020
23
Targeting epimastigotes of Trypanosoma cruzi with a peptide isolated from a phage display random library. 61
31917970 2020
24
Trypanocidal Activity of Flavanone Derivatives. 61
31963596 2020
25
The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History. 61
31963784 2020
26
A role for hepcidin in the anemia caused by Trypanosoma brucei infection. 61
31919087 2020
27
Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association. 61
31906333 2020
28
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo. 61
31986140 2020
29
Blood signatures for second stage human African trypanosomiasis: a transcriptomic approach. 61
32000760 2020
30
Monitoring the presence of trypanosomes' DNA - Including Trypanosoma brucei gambiense DNA - From the midguts of riverine Glossina trapped in the south east outskirts of Kinshasa City (Democratic Republic of Congo). 61
31689541 2020
31
Expression, purification and characterisation of Trypanosoma congolense metacaspase 5 (TcoMCA5) - a potential drug target for animal African trypanosomiasis. 61
31377239 2019
32
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis. 61
31714776 2019
33
The impact of vector migration on the effectiveness of strategies to control gambiense human African trypanosomiasis. 61
31805051 2019
34
Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes. 61
31007068 2019
35
Optimising targets for tsetse control: Taking a fly's-eye-view to improve the colour of synthetic fabrics. 61
31830039 2019
36
Trypanosoma brucei gambiense Group 2: The Unusual Suspect. 61
31668893 2019
37
Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide. 61
31545969 2019
38
The Flipside of Eradicating a Disease; Human African Trypanosomiasis in a Woman in Rural Democratic Republic of Congo: A Case Report. 61
31835660 2019
39
Geoclimatology and sleep in Africa: A mini-review. 61
31253360 2019
40
Parasitological, serological and molecular survey of camel trypanosomiasis in Somalia. 61
31864389 2019
41
Scientometric analysis of global trypanosomiasis research: 1988-2017. 61
31831393 2019
42
Efficacy of a topical combination of fipronil-permethrin against Rhodnius prolixus on dogs. 61
31765865 2019
43
Molecular Prevalence and Epidemiology of Trypanosoma evansi Among Cattle in Peninsular Malaysia. 61
31797192 2019
44
Chagas Disease: Chronic Chagas Cardiomyopathy. 61
31983471 2019
45
Oligopeptidase B, a missing enzyme in mammals and a potential drug target for trypanosomatid diseases. 61
31628976 2019
46
Screening Strategies for a Sustainable Endpoint for Gambiense Sleeping Sickness. 61
31876949 2019
47
Associations of mental disorders and neurotropic parasitic diseases: a meta-analysis in developing and emerging countries. 61
31805904 2019
48
Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness. 61
31804484 2019
49
Modeling antimalarial and antihuman African trypanosomiasis compounds: a ligand- and structure-based approaches. 61
31760561 2019
50
Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics. 61
31670951 2019

Variations for Trypanosomiasis

Expression for Trypanosomiasis

Search GEO for disease gene expression data for Trypanosomiasis.

Pathways for Trypanosomiasis

Pathways related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 TNF TLR9 TLR2 MYD88 IL6 IL4
2
Show member pathways
13.6 TNF IL6 IL4 IL1B IL10 IFNG
3
Show member pathways
13.53 TNF TLR9 TLR2 MYD88 IL6 IL4
4
Show member pathways
13.47 TNF MYD88 IL6 IL4 IL1B IL10
5
Show member pathways
13.36 TNF IL6 IL4 IL1B IL10 CXCL8
6
Show member pathways
13.29 TNF TLR9 TLR2 MYD88 IL4 IL1B
7
Show member pathways
13.26 TNF TLR9 TLR2 MYD88 KNG1 IL6
8
Show member pathways
13.05 TNF TLR2 MYD88 IL6 IL1B CXCL8
9
Show member pathways
12.99 TNF IL6 IL4 IL1B IL10 IFNG
10
Show member pathways
12.98 TNF TLR9 TLR2 MYD88 IL6 IL1B
11 12.94 TNF TLR9 TLR2 MYD88 IL6 IL1B
12
Show member pathways
12.87 TNF MYD88 IL6 IL1B IFNG CXCL8
13
Show member pathways
12.82 TNF TLR9 TLR2 MYD88 IL6 IL1B
14
Show member pathways
12.75 TNF TLR2 IL6 IL4 IL1B IL10
15
Show member pathways
12.72 TNF IL6 IL1B IL10 IFNG CCL2
16
Show member pathways
12.69 TNF TLR9 TLR2 MYD88 IL6 IL4
17
Show member pathways
12.67 TNF TLR9 TLR2 MYD88 IL1B
18 12.54 TNF TLR9 TLR2 MYD88 IL4 IL1B
19
Show member pathways
12.47 TNF MYD88 IL6 IL1B IFNG CXCL8
20
Show member pathways
12.47 TNF TLR2 IL6 IL4 IL1B IFNG
21
Show member pathways
12.46 TNF IL6 IL10 CXCL8 CCL2
22
Show member pathways
12.46 TNF IL6 IL4 IL1B IFNG CCL2
23
Show member pathways
12.45 TNF TLR2 MYD88 IL4 IL1B IL10
24 12.43 TNF MYD88 IL1B CXCL8
25
Show member pathways
12.43 TNF TLR9 TLR2 MYD88 IL6 CXCL8
26
Show member pathways
12.42 IL6 IL4 IL10 IFNG
27 12.42 TNF MYD88 IL6 IL1B CXCL8
28
Show member pathways
12.42 TNF IL6 IL4 IL1B IL10 IFNG
29 12.39 TNF MYD88 IL6 IL1B CXCL8 CCL2
30
Show member pathways
12.38 TNF TLR2 MYD88 IL6 IL1B CXCL8
31
Show member pathways
12.37 TNF TLR9 MYD88 IL6 IL1B IL10
32 12.32 TNF TLR9 TLR2 IL6 IFNG
33 12.31 TNF IL6 IL1B IL10 CXCL8
34 12.31 TNF TLR9 TLR2 MYD88 IL6 IL1B
35
Show member pathways
12.23 TNF TLR9 TLR2 IL6 IL1B IL10
36
Show member pathways
12.22 TNF TLR2 IL6 IL4 IL1B IFNG
37 12.19 TNF IL1B IFNG CCL2
38 12.18 TNF MYD88 IL6 IL1B IL10 CXCL8
39 12.17 TNF IL6 IL4 IL1B IFNG CXCL8
40 12.15 TNF IL6 IL4 IL10 IFNG
41 12.11 TNF IL6 IL4 IL1B IL10 CXCL8
42
Show member pathways
12.1 HPR HP APOL1 APOA1 ALB
43 12.09 TNF IL6 IL1B CCL2
44 12.08 TNF IL6 IL1B CXCL8 CCL2
45 12.06 IL6 IL1B IFNG CXCL8
46 12.04 TNF MYD88 IL1B CXCL8
47 12.03 TNF IL6 IL4 IL1B
48 12.03 TNF TLR2 IL6 IL1B IL10 IFNG
49
Show member pathways
12.03 TNF TLR9 TLR2 MYD88 IL6 IL4
50 11.97 MYD88 IL6 IL1B IFNG CXCL8

GO Terms for Trypanosomiasis

Cellular components related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF TLR9 KNG1 IL6 IL4 IL1B
2 endoplasmic reticulum lumen GO:0005788 9.65 KNG1 IL6 APOL1 APOA1 ALB
3 blood microparticle GO:0072562 9.63 KNG1 HPR HP APOL1 APOA1 ALB
4 extracellular space GO:0005615 9.47 TNF KNG1 IL6 IL4 IL1B IL10
5 spherical high-density lipoprotein particle GO:0034366 9.32 HPR APOA1

Biological processes related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.38 TLR9 TLR2 MYD88 IL6 IL4 IL1B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF TLR9 TLR2 IL6 IL4 IL1B
3 negative regulation of cell proliferation GO:0008285 10.14 TLR2 IL6 IL1B IL10 CXCL8
4 post-translational protein modification GO:0043687 10.11 KNG1 IL6 APOL1 APOA1 ALB
5 defense response to bacterium GO:0042742 10.06 TNF TLR9 MYD88 IL10 HP
6 cellular protein metabolic process GO:0044267 10.04 KNG1 IL6 APOL1 APOA1 ALB
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 TNF TLR9 MYD88 IL1B
8 positive regulation of gene expression GO:0010628 10.03 TNF TLR9 TLR2 MYD88 IL6 IL4
9 response to lipopolysaccharide GO:0032496 10.02 TLR2 IL1B IL10 IDO1
10 cytokine-mediated signaling pathway GO:0019221 10.02 TNF IL6 IL4 IL1B IL10 CXCL8
11 receptor-mediated endocytosis GO:0006898 10 HPR HP APOL1 APOA1 ALB
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 TNF IL6 IL1B IL10
13 defense response to Gram-positive bacterium GO:0050830 9.96 TNF TLR2 MYD88 IL6
14 response to organic substance GO:0010033 9.95 TNF IL10 HPR HP
15 positive regulation of inflammatory response GO:0050729 9.94 TNF TLR9 TLR2 IL1B
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF TLR9 TLR2 MYD88 IL6 IL1B
17 cellular response to organic cyclic compound GO:0071407 9.92 TNF IL1B CCL2
18 regulation of insulin secretion GO:0050796 9.92 TNF IL1B IFNG
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 IL4 IFNG
20 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
21 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL4 IL1B
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF TLR9 TLR2 IL1B
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF IL1B IFNG
24 toll-like receptor signaling pathway GO:0002224 9.88 TLR9 TLR2 MYD88
25 humoral immune response GO:0006959 9.88 TNF IL6 IFNG CCL2
26 protein kinase B signaling GO:0043491 9.87 TNF IL1B CCL2
27 cellular response to lipopolysaccharide GO:0071222 9.87 TNF MYD88 IL6 IL1B IL10 CXCL8
28 negative regulation of interleukin-6 production GO:0032715 9.86 TNF TLR9 IL10
29 positive regulation of interleukin-6 secretion GO:2000778 9.86 TNF TLR2 IL1B
30 positive regulation of phagocytosis GO:0050766 9.86 TNF IL1B IFNG APOA1
31 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.85 TLR9 TLR2 MYD88
32 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
33 microglial cell activation GO:0001774 9.85 TNF TLR2 IFNG
34 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 TNF TLR2 IL1B CCL2
35 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
36 positive regulation of interleukin-12 production GO:0032735 9.83 TLR9 TLR2 IFNG IDO1
37 positive regulation of glial cell proliferation GO:0060252 9.81 TNF IL6 IL1B
38 astrocyte activation GO:0048143 9.8 TNF IL1B IFNG
39 positive regulation of chemokine production GO:0032722 9.8 TNF TLR9 TLR2 IL6
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 TNF IL1B IFNG
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 TNF IL1B IL10
42 positive regulation of neuroinflammatory response GO:0150078 9.77 TNF IL6 IL1B
43 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.75 IL10 APOA1
44 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.75 TLR9 IL1B
45 negative regulation of amyloid-beta clearance GO:1900222 9.75 TNF IFNG
46 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
47 positive regulation of chemokine biosynthetic process GO:0045080 9.75 TNF IL1B IFNG
48 negative regulation of interleukin-8 production GO:0032717 9.74 TLR9 IL10
49 negative regulation of lipid storage GO:0010888 9.74 TNF IL6
50 endothelial cell apoptotic process GO:0072577 9.74 TNF IL10

Molecular functions related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling pattern recognition receptor activity GO:0008329 9.26 TLR9 TLR2
2 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL1B IL10 IFNG
3 Toll-like receptor binding GO:0035325 9.16 TLR2 MYD88
4 hemoglobin binding GO:0030492 8.96 HPR HP

Sources for Trypanosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....